phosphorylcholine has been researched along with Sepsis in 12 studies
Phosphorylcholine: Calcium and magnesium salts used therapeutically in hepatobiliary dysfunction.
phosphocholine : The phosphate of choline; and the parent compound of the phosphocholine family.
Sepsis: Systemic inflammatory response syndrome with a proven or suspected infectious etiology. When sepsis is associated with organ dysfunction distant from the site of infection, it is called severe sepsis. When sepsis is accompanied by HYPOTENSION despite adequate fluid infusion, it is called SEPTIC SHOCK.
| Excerpt | Relevance | Reference |
|---|---|---|
| "Patients with acute respiratory distress syndrome (ARDS) have a deficiency of surfactant." | 2.68 | Aerosolized surfactant in adults with sepsis-induced acute respiratory distress syndrome. Exosurf Acute Respiratory Distress Syndrome Sepsis Study Group. ( Anzueto, A; Baughman, RP; Guntupalli, KK; Lemaire, F; Long, W; Pattishall, EN; Raventós, AA; Weg, JG; Wiedemann, HP; Zaccardelli, DS, 1996) |
| "Miltefosine was orally administered at doses of 15 and 30 mg/kg/day after, at the time of, and before bacterial challenge for 3-5 days." | 1.35 | In vitro and in vivo activity of miltefosine against penicillin-sensitive and -resistant Streptococcus pneumoniae strains. ( Del Prado, G; Gracia, M; Huelves, L; Ponte, C; Rodríguez-Cerrato, V, 2008) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 1 (8.33) | 18.7374 |
| 1990's | 4 (33.33) | 18.2507 |
| 2000's | 3 (25.00) | 29.6817 |
| 2010's | 3 (25.00) | 24.3611 |
| 2020's | 1 (8.33) | 2.80 |
| Authors | Studies |
|---|---|
| Cheng, Z | 1 |
| Abrams, ST | 1 |
| Toh, J | 1 |
| Wang, SS | 1 |
| Downey, C | 1 |
| Ge, X | 1 |
| Yu, Q | 1 |
| Yu, W | 1 |
| Wang, G | 1 |
| Toh, CH | 1 |
| Ramos-Sevillano, E | 1 |
| Urzainqui, A | 1 |
| Campuzano, S | 1 |
| Moscoso, M | 1 |
| González-Camacho, F | 1 |
| Domenech, M | 1 |
| Rodríguez de Córdoba, S | 1 |
| Sánchez-Madrid, F | 1 |
| Brown, JS | 1 |
| García, E | 1 |
| Yuste, J | 1 |
| Gang, TB | 1 |
| Hanley, GA | 1 |
| Agrawal, A | 1 |
| Huelves, L | 1 |
| Del Prado, G | 1 |
| Gracia, M | 1 |
| Rodríguez-Cerrato, V | 1 |
| Ponte, C | 1 |
| Ferguson, LM | 1 |
| Dreisbach, AW | 1 |
| Csongrádi, E | 1 |
| Juncos, LA | 1 |
| Fulop, T | 1 |
| McDaniel, LS | 1 |
| Benjamin, WH | 1 |
| Forman, C | 1 |
| Briles, DE | 1 |
| Doig, C | 1 |
| Weg, JG | 2 |
| Balk, RA | 1 |
| Tharratt, RS | 1 |
| Jenkinson, SG | 1 |
| Shah, JB | 1 |
| Zaccardelli, D | 1 |
| Horton, J | 1 |
| Pattishall, EN | 2 |
| Anzueto, A | 1 |
| Baughman, RP | 1 |
| Guntupalli, KK | 1 |
| Wiedemann, HP | 1 |
| Raventós, AA | 1 |
| Lemaire, F | 1 |
| Long, W | 1 |
| Zaccardelli, DS | 1 |
| Imperatore, F | 1 |
| Postiglione, M | 1 |
| Diurno, F | 1 |
| Cirillo, F | 1 |
| Liguori, G | 1 |
| Pica, M | 1 |
| Speer, CP | 1 |
| Robertson, B | 1 |
| Halliday, HL | 1 |
| Kukkonen, AK | 1 |
| Virtanen, M | 1 |
| Järvenpää, AL | 1 |
| Pokela, ML | 1 |
| Ikonen, S | 1 |
| Fellman, V | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| A Clinical Trial of Nebulized Surfactant for the Treatment of Moderate to Severe COVID-19[NCT04362059] | 20 participants (Actual) | Interventional | 2020-06-18 | Completed | |||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
3 trials available for phosphorylcholine and Sepsis
| Article | Year |
|---|---|
Safety and potential efficacy of an aerosolized surfactant in human sepsis-induced adult respiratory distress syndrome.
Topics: Adult; Aerosols; Aged; APACHE; Double-Blind Method; Drug Administration Schedule; Drug Combinations; | 1994 |
Aerosolized surfactant in adults with sepsis-induced acute respiratory distress syndrome. Exosurf Acute Respiratory Distress Syndrome Sepsis Study Group.
Topics: Administration, Inhalation; Aerosols; Double-Blind Method; Drug Combinations; Fatty Alcohols; Female | 1996 |
Randomized trial comparing natural and synthetic surfactant: increased infection rate after natural surfactant?
Topics: Biological Products; C-Reactive Protein; Drug Combinations; Fatty Alcohols; Female; Humans; Infant, | 2000 |
9 other studies available for phosphorylcholine and Sepsis
| Article | Year |
|---|---|
Complexes between C-Reactive Protein and Very Low Density Lipoprotein Delay Bacterial Clearance in Sepsis.
Topics: Aged; Animals; Bacteremia; C-Reactive Protein; Disease Models, Animal; Female; Humans; Kupffer Cells | 2020 |
Pleiotropic effects of cell wall amidase LytA on Streptococcus pneumoniae sensitivity to the host immune response.
Topics: Animals; Bacterial Capsules; Bacterial Proteins; Cell Wall; Complement Activation; Complement C3; Co | 2015 |
C-reactive protein protects mice against pneumococcal infection via both phosphocholine-dependent and phosphocholine-independent mechanisms.
Topics: Animals; Bacterial Load; C-Reactive Protein; Disease Models, Animal; Male; Mice, Inbred C57BL; Mutan | 2015 |
In vitro and in vivo activity of miltefosine against penicillin-sensitive and -resistant Streptococcus pneumoniae strains.
Topics: Animals; Anti-Bacterial Agents; Bacteriological Techniques; Dose-Response Relationship, Drug; Mice; | 2008 |
Recurring extracorporeal circuit clotting during continuous renal replacement therapy in fungal sepsis: successful treatment with argatroban.
Topics: Antifungal Agents; Antithrombins; Arginine; Blood Coagulation; Coronary Artery Bypass; Humans; Male; | 2013 |
Blood clearance by anti-phosphocholine antibodies as a mechanism of protection in experimental pneumococcal bacteremia.
Topics: Animals; Antibodies, Bacterial; Blood Bactericidal Activity; Choline; Dose-Response Relationship, Im | 1984 |
Aerosolized surfactant in sepsis-induced adult respiratory distress syndrome.
Topics: Drug Combinations; Fatty Alcohols; Humans; Phosphorylcholine; Polyethylene Glycols; Pulmonary Surfac | 1995 |
The instillated surfactant in the treatment of sepsis-induced ARDS: case report.
Topics: Bronchi; Drug Combinations; Fatty Alcohols; Humans; Phosphorylcholine; Polyethylene Glycols; Pulmona | 1999 |
Randomized trial comparing natural and synthetic surfactant: increased infection rate after natural surfactant?
Topics: Biological Products; Drug Combinations; Fatty Alcohols; Humans; Infant, Newborn; Infant, Premature; | 2000 |